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Abstract
CDX1 and CDX2 are possibly predictive biomarkers in colorectal cancer. We combined digitally-guided (next
generation) TMA construction (ngTMA) and the utility of digital image analysis (DIA) to assess accuracy,
tumour heterogeneity and the selective impact of different combined intensity-percentage levels on progno-
sis.CDX1 and CDX2 immunohistochemistry was performed on ngTMAs covering normal tissue, tumour centre
and invasive front. The percentages of all epithelial cells per staining intensity per core were analysed digi-
tally. Beyond classical prognosis analysis following REMARK guidelines, we investigated pre-analytical condi-
tions, three different types of heterogeneity (mosaic-like, targeted and haphazard) and influences on cohort
segregation and patient selection. The ngTMA-DIA approach produced robust biomarker data with infrequent
core loss and excellent on-target punching. The detailed assessment of tumour heterogeneity could – except
for a certain diffuse mosaic-like heterogeneity – exclude differences between the invasive front and tumour
centre, as well as detect haphazard clonal heterogeneous elements. Moreover, lower CDX1 and CDX2 counts
correlated with mucinous histology, higher TNM stage, higher tumour grade and worse survival (p< 0.01, all).
Different protein expression intensity levels shared comparable prognostic power and a great overlap in
patient selection. The combination of ngTMA with DIA enhances accuracy and controls for biomarker analysis.
Beyond the confirmation of CDX1 and CDX2 as prognostically relevant markers in CRC, this study highlights
the greater robustness of CDX2 in comparison to CDX1. For the assessment of CDX2 protein loss, cut-points
as percentage data of complete protein loss can be deduced as a recommendation.
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Introduction
In a recent bioinformatics and classical tissue micro-
array (TMA) approach performed by Dalerba et al,
the lack of CDX2 in stage II colorectal cancer was
highlighted as a high risk and beneficially treatable
situation [1]. TMA studies such as theirs have had a
significant impact on the investigation of biomarkers
in cancer research [2–5]. Moreover, as mentioned by
the authors, a more quantitative assessment and the
inclusion of different staining intensities in the
evaluation of CDX2 could still help to optimise its
value as a prognostic and predictive biomarker.
Recently, the next-generation tissue microarray
(ngTMA) approach was conceptualised to improve
TMAs from a biomarker point-of-view [6,7]. ngTMA
includes digital pathology and automated arraying
(image-guided coring) for tissue processing steps.
Digital slides can be annotated in a way such that
coring can capture precise histological areas of inter-
est [8,9]. Evaluation of immunohistochemistry by
digital image analysis (DIA) would further help to
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fast-track the discovery of potential prognostic and
predictive biomarkers, in addition to help streamline
workflows and produce objective and reproducible
biomarker data [10]. The combined value of a DIA
approach to TMAs has been underlined by works of
many authors [11–15].
As of yet, there are few if any standards for the
reporting of algorithms and settings, which may
hinder cross-comparison of results from different
studies [14]. The added value of DIA with regard to
the objective quantification of the number of positive
cells across various staining intensity ranges (and
what defines these ranges), and the detection of intra-
tumoural heterogeneity in the context of a large prog-
nostic TMA cohort, has not been explored.
In this study, we aim to investigate CDX2 and its
counterpart CDX1 using a combined ngTMA and
DIA approach to evaluate issues of accuracy of cor-
ing, intra-tumoural heterogeneity and prognosis in a
large cohort of 612 colorectal cancer patients.
Methods
Patients
Six hundred and thirty-six consecutive patients with
primary colon cancer treated at the University Hospi-
tal Erlangen between 2002 and 2010 were retrospec-
tively entered into this study. Twenty-four patients
were excluded due to core loss or small amounts of
tumour material (n< 100 epithelial cells/core) during
TMA processing (Table 1). This led to a study cohort
of 612 patients. Patient information was obtained
from hospital records and included age at diagnosis,
gender, as well as detailed follow-up information
such as postoperative chemo- and/or radiotherapy,
and survival (mean overall survival (OS) 67.5
months). No patient received neoadjuvant therapy,
whilst 238 (38.9%) received post-operative treatment.
Histopathological review of all diagnostic cases was
performed by two pathologists (TTR, CIG). Patient
characteristics can be found in Table S1.
The study is in accordance with the declaration of
Helsinki and ethical guidelines applicable for retro-
spective TMA studies were respected for all
experiments (ethics committee statement 24.01.2005
and 18.01.2012).
Next-generation tissue microarray construction
During review, histological slides containing the
most representative areas of normal colonic tissue,
tumour centre and tumour invasive front were
selected. Corresponding blocks were retrieved from
the archives of the Institute of Pathology (University
Hospital Erlangen). Slides were scanned (Pannoramic
P250, 3DHistech, Hungary). Each slide was then
viewed and annotated using a TMA annotation tool
(Panoramic viewer v15.1. and the corresponding
TMA annotation tool, 3D Histech, Hungary) [7,9].
We chose a diameter of 0.6 mm, which reflects the
area of a high power field (HPF) of a standard micro-
scope (eg, field-of-view number 23–24, aperture
0.575–0.625 mm). Each region was annotated in
duplicate or triplicate as depicted (Figure 1).
To achieve a TMA for tumour microenvironment
studies we placed the marking in such a way that
cores from the tumour centre contain a maximum
ratio of epithelium to stroma, ie as many tumour epi-
thelial cells as possible from each case, and that
cores from the tumour invasive front included 50%
epithelium and 50% stroma (Figure 1a–d).
Once all scanned slides were reviewed, the corre-
sponding donor blocks were loaded into an auto-
mated tissue microarrayer (TMA Grandmaster,
3DHistech, Hungary) and aligned. In total, 13
ngTMAs were constructed.
Immunohistochemistry
ngTMA blocks were sectioned at three micrometers
and immunohistochemistry for CDX1 and CDX2 was
performed (CDX1 primary antibody, sc-19747 (Santa
Cruz, Santa Cruz, CA), dilution 1:50, pre-treatment 5
min steam cooking in EDTA buffer, incubation at
room temperature overnight, secondary antibody,
Histofine Goat 414161F (Nichirei Biosciences Inc.,
Tokyo, Japan); and CDX2 primary antibody
MU392A-UC (Biogenex, San Ramon, CA), dilution
1:100, pre-treatment CC1 buffer (Ventana Medical
Systems Inc., Tucson, AZ) for 52 min at 95 8C man-
ually or on an automated immunostainer (Benchmark,
Table 1. Accuracy of punching during tissue microarray construction using the ngTMA approach
Region of interest Cores in total Cores with target Cores without target Loss of cores
Tumour centre 1909 1825 (95.6%) 32 (1.7%) 52 (2.7%)
Invasive front 1874 1597 (85.2%) 214 (11.4%) 63 (3.4%)
Normal tissue 1245 1150 (92.4%) 77 (6.2%) 18 (1.4%)
Total amount 5028 4572 (90.9%) 323 (6.4%) 133 (2.7%)
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Ventana Medical Systems Inc., Tucson, AZ), respec-
tively. Colourisation was achieved with DAB and
counterstaining with haematoxylin.
Digital image analysis
The Definiens Tissue Studio Software (Action library
version 3.6.1., Definiens AG, Munich, Germany) was
used for the image analysis of 13 TMA slides.
First, the Composer module, a machine-learning
approach to segregate tumour, normal tissue, stroma
and whitespace, was applied and all cores were then
classified accordingly. The detection of these areas
was visually checked for all cores using the Tissue
Studio Region of Interest (ROI) Correction and then
manually corrected to include digitally undetected
tumour cells and exclude staining artefacts. This
workflow was used for all cases and checked by two
pathologists (CIG, TTR).
Secondly, we excluded stroma and whitespace and
selected tumour and normal tissue as the ROIs for
the cellular analysis (Figure 2).
Thirdly, the same Tissue Studio nuclear algorithm
was used in all 13 TMA slides for staining quantifi-
cation. In brief, the nuclei within in the ROIs were
detected by setting the staining thresholds (haematox-
ylin, IHC) and the approximate nucleus size (supple-
mentary material, Table S2). Furthermore, the
nucleus classification allowed an automated three-
tiered distinction of IHC marker intensities. For nor-
malisation 12 differently intensity-labelled reference
areas of the ROI for each TMA block were approved.
The positive nuclei were sub-classified automatically
as nucleus low (yellow), nucleus medium (orange)
and nucleus high (dark red). During this step, up to
47 settings were necessary (Table S2). We realised
slight variations of haematoxylin, DAB intensity and
background and adapted to it with the de novo appli-
cation of the algorithm to each TMA slide of CDX1
and CDX2. The cross-calibration from one slide to
another based on 12 reference areas was assisted and
confirmed by SN and CIG.
Finally, the results were automatically arranged
and available for further statistical classifications.
Categories of protein loss
We defined protein loss in three categories, decreas-
ing to lower percentages of staining intensities. Cate-
gory 1: Percentage of complete negative cells.
Negative cells were defined as free of any positivity,
independent of staining intensity (suitable to judge
complete protein loss). Category 2: Percentage of
almost negative cells. Negative and weakly stained
cells were included and separated from moderately
and strongly stained cells (suitable to judge severe
drop of protein expression). Category 3: Percentage
of moderately negative cells. This considers negative,
weak and moderate staining as negative and excludes
only strongly stained nuclei as the positive counter-
part (suitable to judge a slight drop of protein
expression).
Statistics
Descriptive statistics were performed to determine
the mean and standard deviation of the above-
mentioned categories. Basic statistics include Pear-
son’s correlation and the unpaired Student’s t-test
after testing for normal distribution with the
Kolmogorov-Smirnov-Test. The interclass correla-
tions (reliability) were assessed using the Cochrane
alpha test with values approaching 1.0 indicating a
stronger correlation. Non-parametric Wilcoxon Rank
Sum tests were used to analyse the association
between protein expression values and clinic-
pathological features. Log-rank test and Cox regres-
sion analysis were carried out to determine the effect
of CDX1 and CDX2 protein expression and overall
survival (OS). OS was measured from the time of
diagnosis until time of death, with censored patients
Figure 1. Annotation of whole slide images using the tissue microarray tool with a diameter of 0.6 mm corresponding to single high
power fields (HPF). (a) Overview of the slide (13), (b) annotation representing normal tissue (403), (c) annotation representing
tumour centre (403), (d) annotation representing invasive front (403).
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Figure 2. CDX1 and CDX2 immunohistochemistry and image analysis at different steps. Left column: original immunohistochemistry
pictures. Middle column: Step of digital tissue recognition in regions of interest. Right column: Attribution of different nuclear inten-
sity levels to each recognised normal or tumour epithelial cell (blue: negative, yellow: low positive, orange: medium positive, red-
brown: strong positive).
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being alive or lost-to-follow-up. To argue for the use
of continuous scaling our study doesn’t provide spe-
cific cut-off determination. Only in Figure 5 was the
cohort split using the median as a very generalised
threshold. All tests were two-sided. No adjustment
for multiple comparisons was performed [16,17]. p-
values <0.01 were considered statistically significant.
Analyses were made on SPSS
VR
version 22 (IBM,
Armonk, New York) and SAS (V9.4, The SAS Insti-
tute, Cary, NC).
Results
Accuracy of the ngTMA approach
Table 1 underlines the accuracy of ngTMA construc-
tion based on digitally annotated slides. In total,
5028 cores were included in the TMA blocks. Core
loss was threefold lower as compared to values from
the literature with regard to core loss in regular
TMAs [18]. On-target punching showed the highest
accuracy for tumour centre, whereas punching of the
invasive front was more challenging, as expected.
Table 2 details the accuracy of the punching based
on the cell numbers after DIA for CDX1 and CDX2.
For CDX1, the invasive front contains approximately
half the amount of cells (56.9%) in comparison to
the centre. Similarly, for CDX2, the ratio of cells
found in the tumour invasive front is approximately
half the number of cells within the tumour centre
(53.9%). These results are in line with the intended
capture of 50% epithelium and 50% stroma for cores
derived from the invasive front.
Interestingly, the cell numbers for CDX1 are gen-
erally higher than CDX2, which is caused by less
contrast of CDX1 to the surrounding cytoplasmic
staining and less sharp nuclear limits, leading to
interpolations of nuclei by the software. As a control,
a manual nuclear count highlighted the better
Table 2. Detailed overview of numbers of detected cells per
region of interest
Cell counts per core
Protein Region of interest Mean STD ICC
CDX1 Tumour centre 2925 61524 0.735
Invasive front 1665 61211 0.706
Normal 2138 61006 0.522
CDX2 Tumour centre 2026 61062 0.785
Invasive front 1091 6849 0.697
Normal 1934 61177 0.678
Inter-class correlation (ICC) evaluates the concordance of cell densities in
the punched triplicates (Tumour centre, Invasive front) and duplicates
(Normal).
Figure 3. Scheme of three different kinds of visualised hetero-
geneity in tumour cell composition of a primary tumour. (a)
Mosaic-like heterogeneity form with diffuse intermingling cells
at different intensity levels. (b) During ngTMA construction, we
decided to search for possible differences between the tumour
centre and the invasive front, which is a classical approach to
the study, eg hypoxia related effects or simply the diagnostic
background of biopsies versus resection specimens. Here, high-
lighted as decreased intensity levels to the periphery. In this
way, an assumed and experimentally targeted heterogeneity
was tested. (c) Haphazard heterogeneity takes place, if certain
areas (low right) are outside the usual expected spectrum of
the rest of the tumour staining. This kind of heterogeneity was
originally the main argument against the use of TMA for this
purpose [3]. However, it is currently accepted that an increased
number of cores per tumour can balance this effect [23]. Addi-
tionally, we show how to quantify and outline such differences
and cases. Of note, any kind of haphazard heterogeneity can be
transferred to a targeted heterogeneity, if, eg immunohisto-
chemical analysis is used as the basis for ngTMA construction.
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correlation to CDX2 than CDX1 values (supplemen-
tary material). Hence, to reduce this limitation of
slightly overestimated CDX1 positivity, we relied on
the percentages as less cell-count dependent values.
Human visual control of software application
during the ngTMA-DIA workflow
Automation and software support steps during
ngTMA construction, eg merging tools and punching
point definition worked as robustly as published pre-
viously [7,9]. During ROI selection, approximately
one half and one third of the ngTMA cores had to be
adapted manually to cover the normal or tumour tis-
sue area for CDX1 and CDX2, respectively. Haema-
toxylin, diamino benzidine (DAB) and background
varied slightly across the 13 TMA slides and contrib-
uted to undulations of up to 3.3% and 2.3% of the
immunohistochemistry thresholds of CDX1 and
CDX2 (Table S2, with possible values for the thresh-
olds from 0 to 3). A calibration step provided by the
DIA algorithm setup and based on judging differently
stained areas by two experts (SN and CIG) could out-
line and instantaneously exclude these variations for
further statistics.
Pre-analytical and storage-dependent influences
Tissue blocks were stored at room temperature for 5–
13 years (mean 8.9 years). The categories of total
percentage negativity in CDX1 and CDX2 correlated
slightly with the age of formalin-fixed paraffin-
embedded blocks (Pearson correlation r5 0.097 and
r5 0.133, p5 0.017 and p5 0.001, respectively)
indicating a partial loss in immune reactivity over
time.
To test a possible influence of fixation times, we
used the weekday of the surgical intervention as a
Figure 4. Graphs for heterogeneity analysis: (a, b) Histograms of different intensity levels of all counted tumour cells across the com-
plete study visualise the expected extent of mosaic-like tumour heterogeneity. Of note, the values show a dome shaped distribution
in intensity levels. In CDX1 almost all cases showed a mosaic from negative to strong positive cells. The same accounts for CDX2
except the presence of more complete negative cases lacking any positivity, which might explain the higher numbers of complete
negative tumour cells in this histogram. In normal tissues the negative cell counts stem from intermingled negative cells predomi-
nantly at the crypt basis. (c, d) Ascendingly plotted standard deviations amongst all replicates (six cores) per tumour for all categories
of CDX1 and CDX2. Of note, Category 1 in CDX2 showed the lowest maximum values.
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surrogate marker. Due to the standardised processing
times, surgical specimens from Fridays are regularly
fixed for 72 h, whereas interventions from other days
occur within 24 h of fixation. Throughout all inten-
sity categories of staining for both markers, the dif-
ferences in the means were less than 2% and
statistically not significant.
Assessment of tumour heterogeneity using the
detailed data of a complete ngTMA-DIA workflow
Using TMA techniques, researchers are confronted
with at least three different types of heterogeneity
already present in the primary tumour (Figure 3).
Diffuse mosaic-like heterogeneity results from the
attribution of different staining intensities to single
cells by the high resolution of the Definiens Software
(Figure 2, right column). These spectra of intensities
are summarised in the histograms of Figure 4a, b
across the complete study. CDX1 showed less dis-
criminatory power between completely negative and
strongly positive cells than CDX2. Each ROI per
core showed diffuse intensity differences from cell to
cell with a logical decrease of this variability in the
rather negative cores.
A hypothesis driven assumption of heterogeneity
was considered during ngTMA construction, as
tumour centres and invasive fronts were punched sep-
arately. This targeted heterogeneity could be
excluded for both biomarkers. There was no differ-
ence in CDX1 expression between the tumour centre
and tumour invasive front, neither with regard to the
total percentage of positive cells (88.5% and 88.1%),
the percentage of weakly stained cells (21.6% and
22.0%, respectively), moderately stained cells (38.4%
and 38.5%, respectively) or strongly stained cells
(28.5% and 27.6%, respectively) building up the
three categories. Similar results were found for
CDX2, with a total percentage of positive cells of
32.7% versus 31.1% in the tumour centre and front,
respectively, followed by 9.9% and 6.7% for weakly
stained cells, 15.7% and 15.0% for moderately
stained cells and 7.1% and 9.4% for strongly stained
cells.
This allowed us to pool the two triplicate sets of
the tumour centre and the invasive front for further
statistics.
The detailed ngTMA-DIA data helped to check for
morphologically and anatomically inexplicable hap-
hazard heterogeneity as follows: high interclass cor-
relation coefficients were achieved as concordance
rates between the randomly sampled replicate cores
of normal tissue, tumour centre and invasive front
(Table 3). Additionally, standard deviations of these
replicates were plotted for each intensity category of
CDX1 and CDX2 (Figure 4c, d). Hence, the devia-
tion of single cores by6 2STD from the mean of all
six cores could be determined (Table 3). For both
CDX1 and CDX2, outliers were exceedingly rare or
even non-existent (Category1, completely negative
cells, CDX2).
Prognostic impact of CDX1 and CDX2 and positive
correlation
The prognostic impact of each staining intensity cate-
gory was assessed for CDX1 and CDX2.
Table 4 summarises the p-values for the associa-
tion of CDX1 and CDX2 with clinico-pathological
features within the different intensity categories. Con-
sequently, the collective is stratified differently, but
with narrowing edges for the completely positive or
negative cases (Figure 5a,b).
As expected, CDX1 and CDX2 were significantly
and positively correlated throughout all categories.
The strongest correlation was found between the per-
centage of category 1 for CDX2 and category 2
CDX1 expression (Pearson correlation, r5 0.198,
p< 0.001).
Table 3. Inter-class correlation (ICC) between cores taken from different regions of interest at the four-tiered intensity levels for
CDX1 and CDX2
Total negativity Weak intensity Moderate intensity Strong intensity









CDX1 Tumour centre 0.800 7.8% (48/612) 0.822 4.1% (25/612) 0.795 2.0% (12/612) 0.846 1.6% (10/612)
Invasive front 0.794 0.833 0.796 0.830
Normal 0.785 0.664 0.680 0.724
CDX2 Tumour centre 0.923 0.0% (0/612) 0.867 4.7% (29/612) 0.875 2.0%(12/612) 0.911 4.4% (27/612)
Invasive front 0.900 0.813 0.857 0.883
Normal 0.911 0.859 0.837 0.904
Percentages and case numbers of possible ‘patchy’ heterogeneity based on a core by core analysis (Confidential interval: mean across six tumour cores6 2 STD
of total cores). Outlined for both biomarkers and each intensity level.
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CDX1. Results for CDX1 are best encompassed in
Category 1. They highlight strong associations with a
significantly greater frequency of female gender
(p5 0.0339), mucinous histology (p< 0.0001), higher
tumour grade (p< 0.0001), more advanced pT
(p5 0.0046), more node metastasis (p5 0.0092),
more distant metastasis (p5 0.008), a higher overall
tumour stage (p5 0.0004) and lymphatic invasion
(p5 0.003).
Univariate survival time analysis shows significant
associations between loss of CDX1 and worse overall
survival using all three methods, by analysing the
continuous values of each. Multivariate analysis is
shown in Table S3. Although the relative risk of
death in patients is 2.62 with a lower number of
strongly stained cells, this result was not statistically
significant. Illustrations of survival time differences
using Kaplan-Meier curves are shown in Table S4.
Note that with the categorisation of an otherwise con-
tinuous and normally distributed value, there is no
statistically significant difference in survival for Cat-
egory 1 and 2 when tested using a log-rank test.
CDX2. Results for CDX2 show that the lower the
number of positive cells, regardless of the method
Figure 5. (a, b) Two dimensional cohort plots addressing percentage positivity levels at three different intensity levels. Differences in
patient selections were based on staining intensity categories 1–3, indicating slight, strong or complete loss of positivity in the
tumour cells. The complete patient cohort was sorted in ascending order according to the percentage of positive cells defined. This
graph indicates the number of patients falling above or below a given percentage. For example, a selection of patients in CDX1 based
on a cut-off of 50% is therefore highly likely to be intensity-dependent, whereas a cut-off of 100% negativity in CDX2 is less likely
to be intensity-dependent, with narrowed lines and a substantial number of patients. (c, d) Area-proportional Venn diagrams of over-
lapping patient selection. The cohort was split by median cut-offs into favourable and unfavourable prognostic groups for the differ-
ent intensity categories (1–3) for CDX1 (a) as well as CDX2 (b). Of note, the category 1 in CDX2, meaning complete protein loss,
covers the broadest range of patients. Interestingly, each cut-off definition, whether total, strong or weak protein loss, would lead to
a strong overlap in patients, but to different amounts of outliers as well. However, in direct comparison, the CDX2 categories are
tightened, indicating less dependency on the different intensity definitions than CDX1.
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used to categorise staining intensity, the greater the
likelihood of female gender, mucinous histology,
higher tumour grade, more advanced pT and higher
TNM stage (p< 0.01, all). In terms of OS, Category
1 leads to significant findings suggesting again that
fewer positive cells, regardless of staining intensity,
is a relevant prognostic factor. As shown in Table
S3, CDX2 in this cohort does not have an independ-
ent prognostic effect, when adjusting for the con-
founding effect of TNM stage and postoperative
therapy.
Stratification of the patient cohort at different
intensity categories for CDX1 and CDX2
The impact on patient selection based on the differ-
ent categories is depicted in a graph (Figure 5a, b).
Sorting patients ascendingly according to tumour cell
percentages at different intensity levels shows that,
especially at low intensity levels (category 1 and 2),
values for CDX2 are likely in parallel. This impact
can be transferred to area-proportional Venn dia-
grams (Figure 5c,d), if the individual cut-offs were
used to split the groups into low and high risk
groups. Once again, the coverage of category 1 in
CDX2 to select patients showed the biggest
and therefore best overlap with the other categories
(Figure 5c,d).
Discussion
In an extended bioinformatics approach, Dalerba
et al recently searched for candidate genes as action-
able biomarkers in colorectal cancer. Amongst the 16
candidate genes identified, they found CDX2 to be
the most promising biomarker. With retrospectively
available data about therapy regimens, they intro-
duced a possible predictive role for CDX2. Patients
with a loss of CDX2, which accounted for approxi-
mately 9% of patients, would benefit from an adju-
vant chemotherapy, even in stage II colorectal cancer
[1], which immediately led to demands for further
independent studies augmenting the knowledge and
applicability of these biomarkers in daily routine
[19]. As Dalerba et al pointed out in their analysis,
an appropriate quantification and the implementation
of different staining intensities might play a role for
proper CDX2 assessment.
They cross-validated the whole genome expression
data with a classical TMA technique with two inde-
pendent experienced observers judging the slides. Of
course, REMARK and classical TMA guidelines
were followed in their study [1,20–22], but open
questions remained, especially in preparation for
reading out cases in a clinical trial scenario. Picking
up CDX2 as a high ranked candidate seems reasona-
ble as a lot of structural, enzymatic or even target
proteins appeared in the candidate gene list. How-
ever, CDX1 a second intestinal differentiation
marker, was also identified, but not further investi-
gated. Therefore, we tested both biomarkers in com-
parison on an independent well characterised
colorectal cohort. To add more information, we
decided to use a complete digital pathology workflow
regarding TMA construction as well as DIA. DIA
has been unequivocally shown to be equivalent to
manual scoring [23] and recently outperformed read-
ing by eye in the field of routine breast cancer bio-
markers or oesophageal adenocarcinoma [15,24].
Still, most scenarios of immunohistochemistry
analysis can rely on arbitrarily-grouped percentage-
intensity combinations like the IRS or H-Scores to
Table 4. Association of CDX1 and CDX2 with clinical-pathological features using different thresholds for detection of staining (using
continuous values, no cut-offs)
CDX1 CDX2
Feature Category 1 Category 2 Category 3 Category 1 Category 2 Category 3
Gender * ** ** **
Histological subtype *** ** ** ** * *
Tumour grade *** *** *** *** *** ***
pT ** * ** ** **
pN ** * *
cM/pM **
TNM stage ** * ** *** *** ***











*p< 0.05, **p< 0.001, ***p< 0.0001.
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reach basic biological information [13,25,26]. Other-
wise, it should be considered that values are skipped
in these semi-quantitative systems and significances
reached by multiplication. Therefore, we wanted to
gather information on how to overcome these meth-
ods in terms of more quantification and precision. As
an addendum to the widely accepted REMARK
guidelines [20,22] and established TMA recommen-
dations [21] we integrated a checklist of controls and
complementary statistics (Table 5), which can possi-
bly be used as a backbone for further ngTMA-DIA
trials. Of note, the operator time of DIA software set-
ting and calibration steps still exceeds the time of a
quick manual TMA scoring in incremental steps.
As stated above, our first aim was to evaluate the
digital support during ngTMA construction. The
excellent on-target punching and infrequent core loss
was achieved by core selection at high magnification
(4003) and automation. In general, there was a
strong agreement between the cell counts of replicate
cores, independent of staining intensity. On target
punching achieved best values for tumour centre
(95.6%). The tiny diameter of 0.6 mm might influ-
ence the on-target punching of challenging regions
like the invasive front in comparison to values from
others using ngTMA with 1.5 mm core diameter
(85.2% versus 98% tumour centre and periphery) [8].
The core loss and related patient exclusion was
reduced to a fifth to a third of the 10–15% reported
as a regular amount [21].
Secondly, we assessed possible pre-analytical influ-
ences and tumour heterogeneity as parameters for
biomarker robustness. The small decrease of CDX1
and CDX2 immunoreactivity during long-term stor-
age is negligible. No differences between fixation
times at 24 versus 72 hours could be found. Hence,
both biomarkers seem to be stable in terms of pre-
analytics. Next, we separated three different types of
intra-tumoural heterogeneity, taken into account prior
to ngTMA construction (Figure 3). The mosaic-like
heterogeneity can only be stated if all cells are pro-
portionally counted at their individual staining inten-
sities, as performed with DIA. At a glance, it could
be seen that the CDX2 histogram showed two peaks
separating positive from negative cells, whereas
CDX1 showed a dome-shaped histogram (Figure 4a,
b), indicating a higher discriminatory power of the
CDX2 staining. The analysis of our targeted hetero-
geneity during TMA construction excluded differen-
ces between the tumour centre and the invasive front.
Haphazard heterogeneity in terms of inexplicable out-
liers of single core values were less than 7.8% for
CDX1 and less than 4.7% for CDX2 throughout all
staining intensity levels. Of note, no outlying cores
were found in the category of completely negative
cell percentages in CDX2. With these statistics, we
can decipher that CDX1 and CDX2 appear to be
homogeneously expressed throughout the tumour.
This enables a possible diagnostic access with biopsy
taking.
Table 5. Checklist for complete next-generation tissue microarray – digital image analysis (ngTMA-DIA) workflow
Aim Suggested analysis control Example within this study
Control of construction Provide data highlighting the accuracy of
punched regions of interest
Tumour cell numbers per core in tumour centre
versus invasive front
Control of mosaic like heterogeneity Provide data showing the distribution of
dispersed positive to negative cells
Histograms with three-tiered intensity levels for
each staining were included
Control of targeted heterogeneity Provide data between the different targeted
regions of interest
The targeted differences between tumour centre
versus invasive front were analysed
Control of haphazard heterogeneity Provide data as inter-core-variability ICC values for inter-core-variability have been
generated for each staining. Additionally,
standard deviations were plotted along the
cohort and a case by case search of deviating
cores was performed
Control of intensity and
percentages interplay
Combination of exact percentages of each
intensity category (0–3) considering the
expected biological function
Three categories of protein loss were generated
and its impact on possible patient selection
visualised in a graph
Enhanced statistics’ reliability Increased number of punches enhances the
accuracy of ngTMA biomarker analysis
As different levels of heterogeneity could be
excluded, the mean of all six cores per tumour
was used for further statistics
Admit limitations Put down notes on data acquisition and data
processing using DIA and corresponding
software
Notes on manual tumour area recognition,
differences in cell number attribution between
both stainings, as well as slight threshold
adaptations due to staining and intensity
variations from slide to slide have been
implemented
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The third analysis step enrolled a classical progno-
sis analysis according to REMARK guidelines, but
with an additional focus on the interplay between
staining intensities and percentages in terms of
patient selection. Both CDX1 and CDX2 could be
used as markers for differentiating prognosis in our
patient cohort, which supports their role as possible
tumour suppressors and actionable biomarkers [1,27].
As recommended, we used continuous scaling for sta-
tistics and only generalised median or ROC curve-
based cut-off determination if necessary [21]. Differ-
ent intensity categories were used to separate the
patient cohort. Then, repeated prognosis analyses
were performed and the results re-applied to the
cohort to look for shifts in patient selection. Of note,
using the different intensity categories points towards
the same prognosis, irrespective of the underlying
biomarker, CDX1 or CDX2. However, CDX2 cate-
gory 1, meaning complete protein loss, showed the
greatest significance. This results from the connectiv-
ity of shifted percentages in a given image with a
fixed amount of tumour cells follow a standard beta
distribution [23]. Completely negative cells seem to
be linked to percentages of low positivity and shrink
the percentages of strong positive cells etc. DIA
helps to highlight these shifts of percentages in
between intensity categories, rather than assume both
parameters to be independent variables. The connec-
tivity of the intensity categories is highlighted in
cohort plots. Herein, intensity curves narrow at the
edges of the percentage delineation. This argues
against cut-offs in a mid-range, if robustness and
independency from intensities should matter for a
biomarker. Additionally, great overlaps in patient
selection can be seen in these areas and during cut-
off application on the cohort. Herein, CDX2 showed
again a less intensity dependence on decision making
than CDX1.
The main limitation of this study is a lack of infor-
mation regarding the method of DIA in the literature.
Even amongst recent studies [10,14,15,24,28–36]
using this technique, only a few report details regard-
ing settings and scientific troubleshooting [10,32,33].
Additionally, many studies condense the detailed data
to again simplified values, which could have been
gathered with eye-balling, or are partially hidden for
license/patent processes of industrial-academic col-
laboration [15,30]. Therefore, we aimed to pioneer
transparency, reporting settings and statistical consid-
eration within a complete ngTMA-DIA workflow.
Additionally, our study did not focus on tumour buds
as singular cells or clusters that despite their biologi-
cal relevance contribute only slightly to the numeri-
cal composition of a tumour. The DIA analysis used
relied on complete core analysis of 0.6 mm diameter
corresponding to a classical HPF. Regional loss of
CDX2 expression has been described for tumour
buds [37], which would be a sub-structure, even in
an HPF. Adapted DIA approaches for tumour buds
have recently been proposed based on a multi-
immunofluorescence basis, but were not available for
our study [38].
In conclusion, we can attribute a role as tumour
suppressors to both biomarkers. Several investigated
parameters indicate that CDX2 performs more
robustly than CDX1 in terms of applicability. Our
projected results show that (1) ngTMA is highly
accurate and leads to a low frequency of tissue core
loss, (2) different types of tumour heterogeneity can
be investigated using the combined ngTMA-DIA
workflow and (3) low percentages of CDX1 and
CDX2 positive cells are associated with more aggres-
sive tumour biology and the influence of different
staining intensities on patient selection is much lesser
in CDX2 than in CDX1. Combining all data from
this analysis, we recommend that CDX2 ‘loss’ be
scored as percentage of cells with complete absence
of immunoreactivity.
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Figure S1. Errors during the nuclear detection step of the Definiens Software and their dependency on staining compartmentalisation
Table S1. Patient characteristics (n5 612)
Table S2. DIA settings of the Definiens Tissue Studio Software
Table S3. Multivariable survival time analysis for CDX1 (Category 1: percentage of total cell positivity) and CDX2 (Category 1: percentage
of total cell positivity). HR5 hazard ratio
Table S4. Cut-off scores used to classify cases into low/high values using either ROC-derived cut-off values or median values across the entire
patient cohort. ROC5 receiver operating characteristic
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